0001193125-26-203964
SEC filingNuvation Bio reported its first profitable quarter with $5.4M net income and $3.9M operating income, driven by license revenue from the Eisai agreement and commercial activity — marking a structural shift from R&D investment to monetization.
Revenue for Q1 FY2026 totaled $83.2 million, a substantial increase from $3.1 million in Q1 FY2025. This growth was primarily due to a $58.7 million increase in license revenue resulting from the upfront payment received under the Eisai agreement, along with increases in product supply and royalty revenue. The increase reflects the execution of strategic partnerships and the initiation of commercial activity, rather than organic product sales alone.
Operating income improved to $3.9 million, compared to a loss of $59.0 million in the prior-year period. This shift was enabled by the recognition of license revenue, which more than offset increases in operating expenses — including higher salaries and benefits tied to increased headcount and stock-based compensation, as well as third-party clinical trial costs. The improvement signals a structural inflection: Nuvation Bio’s financial profile is now shaped by revenue generation, not solely by R&D investment.
Net income for the quarter was $5.4 million, reversing a $53.2 million loss in Q1 FY2025. Diluted earnings per share were $0.01, compared to a loss of $0.16 per share in the prior year. These results reflect the impact of license revenue on the bottom line and confirm the company’s ability to achieve GAAP profitability in a single quarter — a milestone directly attributable to partnership execution and commercial readiness.
Net cash provided by operating activities was $5.1 million, a reversal from $42.6 million used in the prior-year period. This positive inflection demonstrates that current operations — supported by license revenue and early commercial revenue — now fund core activities. It validates the sustainability of the new revenue model and reduces reliance on external financing for near-term operations.